The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Rybrevant Faspro
AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) · AMIVANTAMAB 3520 mg/22mL; HYALURONIDASE (HUMAN RECOMBINANT) 44000 mg/22mL · Injection · Subcutaneous · Janssen Biotech, Inc.
NDC 57894-0522-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 22 mL in 1 VIAL, SINGLE-DOSE · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Medicare Part B (ASP)
Payment limit per 5 MG
$40.743
HCPCS J9062 · Jul 1, 2026 quarter · typically ASP + 6%
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761433
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Janssen Biotech, Inc. | AMIVANTAMAB 1600 mg/10mL; HYALURONIDASE (HUMAN RECOMBINANT) 20000 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Janssen Biotech, Inc. | AMIVANTAMAB 2240 mg/14mL; HYALURONIDASE (HUMAN RECOMBINANT) 28000 mg/14mL | Jul 15, 2026 | Sep 2, 2026 |
| Janssen Biotech, Inc. | AMIVANTAMAB 2400 mg/15mL; HYALURONIDASE (HUMAN RECOMBINANT) 30000 mg/15mL | Jul 15, 2026 | Sep 2, 2026 |
| Janssen Biotech, Inc. | AMIVANTAMAB 3520 mg/22mL; HYALURONIDASE (HUMAN RECOMBINANT) 44000 mg/22mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Rybrevant Faspro — NDC 57894-0522-01," retrieved September 3, 2026, https://drugdashboards.com/drug/57894052201.
Free to cite with attribution — see how the data is put together.